% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

  • breezerwave breezerwave Feb 25, 2013 1:11 AM Flag

    Price already discounted for review panel negative recommendation

    Jefferies reiterated ts Buy rating and $5 price target on Dynavax Technologies (NASDAQ: DVAX) ahead of Friday's Heplisav FDA decision.

    "We have revised our scenarios for Friday’s Heplisav FDA decision and added a scenario in which the company receives a complete response letter and refiles in 2Q13 for chronic kidney disease (CKD) patients," the analyst said. "We estimate that this could be approved by early 2014 and would still yield a $5 valuation. We would be buyers on any weakness if a complete response letter is issued on Friday."

16.08-0.14(-0.86%)May 3 4:00 PMEDT